Estrogen suppresses adipogenesis by inhibiting S100A16 expression

Area of Science:

• Endocrinology
• Metabolic Syndrome Research
• Molecular Biology

Background:

• Metabolic syndrome is a cluster of conditions increasing the risk of heart disease, stroke, and type 2 diabetes.
• Estrogen deficiency, particularly after menopause, is linked to metabolic dysfunction and increased adiposity.
• The role of specific molecular mechanisms, such as S100A16, in estrogen's metabolic effects requires further elucidation.

Purpose of the Study:

• To investigate the effects of estradiol (E2) on metabolic syndrome.
• To elucidate the molecular mechanisms underlying E2's actions, focusing on the S100A16 protein.
• To determine if S100A16 mediates E2's influence on adipogenesis.

Main Methods:

• Ovariectomized (OVX) rat models were utilized to simulate estrogen deficiency.
• Mouse embryonic fibroblasts were employed as a cell model for adipogenesis studies.
• Gene expression analysis, including adipocyte markers (PPARγ, aP2, C/EBPα, S100A16), and luciferase assays were performed.

Main Results:

• E2 deficiency in OVX rats led to increased body weight and central abdominal fat accumulation.
• E2 treatment ameliorated these effects under both standard chow and high-fat diet (HFD) conditions.
• E2 significantly decreased the expression of adipocyte marker genes and inhibited adipogenesis.
• Overexpression of S100A16 reversed the inhibitory effect of E2 on adipogenesis, and E2 was found to inhibit S100A16 expression.

Conclusions:

• Estradiol plays a protective role against metabolic syndrome development, reducing body weight gain and central adiposity.
• E2 suppresses adipogenesis, partly through the inhibition of S100A16 expression.
• S100A16 is identified as a key molecular target mediating the anti-adipogenic effects of E2.